{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', 'The GlaxoSmithKline group of companies', '201749', 'TITLE PAGE', 'Division: Worldwide Development', 'Information Type: Protocol Amendment', 'Title:', 'A 24-week treatment, multi-center, randomized, double-blind,', 'double-dummy, parallel group study to compare', 'Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in', 'subjects with chronic obstructive pulmonary disease (COPD)', 'Compound Number: GSK2592356', 'Development Phase:', 'IV', 'Effective Date:', '18-APR-2017', 'Protocol Amendment Number: 03', 'Author (s):', 'PPD', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited', '1']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', 'The GlaxoSmithKline group of companies', '201749', 'Revision Chronology', 'GlaxoSmithKline', 'Date', 'Version', 'Document Number', '2016N277425_00', '2016-SEP-13', 'Original', '2016N277425_01', '2017-FEB-07', 'Amendment No. 1', 'This protocol amendment was created to make the following changes:', 'Regulatory Agency Identifying Number(s): A typographical error in the EudraCT no.', 'corrected. IND no. added', 'Section 4. 1 and Section 4.4: Typographical errors and inconsistencies corrected', 'Inconsistencies between Section 4.4, Section 7.3.1.5 and Section 7. 1revised', 'Section 7.1 Time and Events table:', 'Un-intentional deletion of the (\"x\") were added to confirm that concomitant medications', 'should be reviewed at every clinic visit was corrected.', 'Increased the visit window', 'Typographical error and inconsistencies corrected as described in Appendix 9, Section', '12.9.', 'Section 7.2.2 Critical procedures performed at Screening (Visit 1): To clarify that height', 'and weight are collected at V1 \"Height and weight\" added', 'Section 7.3.2 Spirometry: \"At Screening, before the morning dose of usual COPD', \"medication(s)' added.\", 'Section 7.3.7: Physical activity monitor (study subset)', 'Inconsistency between Section 1, Section 4.1 and Section 7.3.7 revised', '2016N277425_02', '2017-FEB-21', 'Amendment No. 2 Canada', 'ONLY', 'This protocol amendment was created to comply with Health Canada guidelines. They', 'require pharmaceutical manufacturers to expeditiously report domestic cases of unusual', 'failure in efficacy (UFIE) for new drugs to the Marketed Health Products Directorate', '(MHPD) within 15 days of first notification.', 'Changes were made to Section 7.4.1 and Appendix 4.', '2016N277425 03', '2017-APR-18', 'Amendment No. 3', 'This protocol amendment was created to make the following changes:', 'Clarifications concerning study design, stratification, permitted and prohibited COPD', 'medications, stopping criteria, visit windows, chest x-rays performed in the context of', 'the protocol and site professional expertise', 'Rate of COPD exacerbations from tertiary endpoints to exploratory endpoints', 'Addition of an inclusion criterion specific to France', 'Integration of Canadian Amendment 2', 'Correction of typographical errors and inconsistencies', '2']['2018N377698_00', '2016N277425_03', 'CONFIDENTIAL', '201749', 'SPONSOR SIGNATORY', 'PPD', '18 April 2017', 'David Lipson, MD', 'Date', 'Project Physician Leader', 'PPD', '3']\n\n###\n\n", "completion": "END"}